Demcizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Demcizumab?
Monoclonal antibody
Source Humanized (from mouse)
Target DLL4
Identifiers
CAS Registry Number 1243262-17-0
ATC code None
IUPHAR/BPS 8451
Chemical data
Formula C6444H10004N1700O2028S52
Molecular mass 145.3 kDa

Demcizumab /dɛmˈsɪzʉmæb/ is a humanized monoclonal antibody designed for the treatment of cancer.[1]

As of 2015, the drug is being developed by OncoMed Pharmaceuticals in non-small-cell lung cancer as well as pancreatic cancer, in collaboration with Celgene.

Mechanism of action[edit]

Demcizumab blocks Delta-like ligand 4 (DLL4), a ligand of Notch receptors. Notch signaling has been implicated as a key signaling pathway in cancer stem cells. By treating patients with a combination of Demcizumab and a cytotoxic chemotherapy, it is hoped that a more durable anti-tumor response can be achieved than with chemotherapy alone.

References[edit]